bx-471 and Autoimmune-Diseases

Berlex and its parent company, Schering AG, are developing BX-471 (also known as ZK-811752), the lead in a series of non-peptide chemokine receptor 1 (CCR1) antagonists, for the potential treatment of autoimmune diseases, in particular multiple sclerosis (MS) [291682], [376290], [411184]. In March 2000, BX-471 was undergoing phase I trials for the potential treatment of autoimmune diseases [362022]; phase I trials in MS were ongoing in March 2002 [441989], [443941]. Positive results from these trials have been reported and Berlex was planning phase II trials in MS patients as of mid-March 2002 [444906]. In July 2001, Schering estimated filing in the US and EU in 2008 [411184], [416493]. WO-09856771 claims piperazinyl derivatives, pharmaceutical compositions comprising them and their use in the treatment of inflammatory conditions.

Topics: Animals; Autoimmune Diseases; Clinical Trials, Phase I as Topic; Drug Evaluation, Preclinical; Graft Rejection; Humans; Multiple Sclerosis; Phenylurea Compounds; Piperidines; Receptors, CCR1; Receptors, Chemokine; Structure-Activity Relationship; Treatment Outcome

Topics: Animals; Autoimmune Diseases; Humans; Receptors, Chemokine